| Name | Title | Contact Details |
|---|---|---|
Vinay Gidwaney |
Head of Technology | Profile |
Island Gym and Fitness is a Absecon, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Wellframe helps healthcare organizations support people beyond the four walls of care delivery. We provide care transformation services, a patented engagement platform, clinical programs that support the clinical and social determinants of health, and rigorous measurement.
Since our first facility opened in 1970, Life Care`s associates have positively impacted the company`s mission of providing exceptional patient care. Life Care owns or manages more than 200 facilities and employs approximately 40,000 individuals who strive daily to make a difference in the lives of those we serve. Our facilities offer multiple levels of patient care and services, which vary by location. We offer post-acute care and inpatient and outpatient therapy in well-equipped, on-site rehabilitation gyms. We believe that as a privately owned company, Life Care Centers of America stands apart from others. We offer a resident-centered corporate culture with more than 45 years of experience, stability and success. Our modern and well-maintained facilities feature strong multidisciplinary teams, specialty programs and opportunities for continuing education.
Rowan Regional Medical Center is a Salisbury, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.